Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
A hair loss regime consisting of finasteride, minoxidil and microneedling that was started 4 months ago with minimal side effects reported. The user also uses Nizoral once a week.
A man's successful hair regrowth after using finasteride, minoxidil, microneedling, hair supplements, and scalp massages. He noticed significant improvements and is excited about future progress.
The user reported significant hair regrowth after seven months using topical minoxidil 5% combined with 0.1% finasteride and weekly micro needling. The community responded positively, noting visible improvement and discussing the effectiveness of topical versus oral finasteride.
The conversation is about a hair loss treatment protocol involving microneedling, finasteride, RU58841, minoxidil, ketoconazole shampoo, and a scalp massager with oils. Some users advise starting with fewer treatments like finasteride, minoxidil, and microneedling to avoid potential side effects.
RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.
User shared 4.5-month hair loss treatment results using Fin, Minoxidil, and microneedling. Others discussed postponing hair transplant and adjusting microneedling depth.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
The conversation discusses hair regrowth using 0.1% finasteride, 5% minoxidil, 1% retinoid, weekly microneedling, and red light therapy, with noticeable improvement in a short time. One person is curious about the retinoid application process when used with minoxidil.
The conversation discusses using crushed finasteride tablets mixed with topical minoxidil for hair loss treatment. Users share their experiences and opinions on the effectiveness and proper concentration of this method.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
A user shared their 88-day progress using 1.25mg finasteride, topical minoxidil, and weekly 1mm microneedling, noting improvement from NW 4.5 to around NW 3. Another user complimented the progress.
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
The user experienced significant hair regrowth using finasteride (1.25mg daily) and minoxidil (topical and oral) with occasional microneedling. They noted increased libido as a side effect during the first six months.
User shares 4-month progress using finasteride, minoxidil, and microneedling for hair loss. Others discuss body hair, hair transplant possibilities, and user's treatment response.
This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.
The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.
The user is concerned about mixing Pantostin (with Alfatradiol) and Finasteride in a topical solution, fearing a potential toxic reaction or ineffectiveness. They seek advice on whether this combination is safe.
Switching from oral minoxidil back to topical due to heart issues and palpitations. Users discuss experiences with minoxidil and finasteride, with mixed results and concerns about side effects.
The user is considering reducing their finasteride dose from 2.5mg to 1.25mg to make the supply last longer and is concerned about potential changes in results. They have been using the 2.5mg dose for four months.
The user experienced hair regrowth after 5 months using Minoxidil and PRP treatment. They also took various supplements and adjusted their diet to address deficiencies and support hair health.
A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.